Patent · US Active

HIV-1 envelope glycoprotein

US9738688B2 · kind B2 · utility

4Cited by

0References

19Claims

0Family size

Assignees

International AIDS Vaccine Initiative, Inc. · US
THE SCRIPPS RESEARCH INSTITUTE · US
Cornell University · IT

Inventors

Michael Caulfield · Fort Washington, US
Albert Cupo · Stamford, US
Hansi DEAN · Cambridge, US
Simon Hoffenberg · Hartsdale, US
C. Richter King · Washington, US
P. J. Klasse · New York, US
Andre Marozsan · Boston, US
John P. Moore · New York, US
Rogier W. Sanders · Ithaca, US
Andrew Ward · Village of La Jolla, US
Ian A. Wilson · Hitchin, GB
Jean-Philippe Julien · Toronto, CA

Key dates

Filing date	Nov 5, 2013
Grant date	Aug 22, 2017
Priority date	—
Expiry date	Nov 5, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2740/16122
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present application relates to novel HIV-1 envelope glycoproteins, which may be utilized as HIV-1 vaccine immunogens, and antigens for crystallization, electron microscopy and other biophysical, biochemical and immunological studies for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions, which are formulated into the vaccines of the present invention.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.